To Evaluate and Compare the Efficacy of Vidarikanda Churna and Kataka Churna in the Management of Male Sexual Function and Visual Acuity

Background: Eye is an important sense organ. It is very important to protect vision. Aacharya Sushruta described Atimaithuna (excessive sexual activity), in etiological factors causing Netraroga. Excessive sexinduced stress hormones – epinephrine and nor-epinephrine – may damage retinal endothelial cells, inflame eye balls and dilate pupils, over sensitivity to light in the retina and adverse effect on power of vision.Need of study: Most ophthalmologists can effectively diagnose and treat blurred vision caused by glaucoma, cataracts, presbyopia, diabetes, macular degeneration or retinal detachment. But for sexually exhausted people with blurred vision, the problem goes undiagnosed and treated.Aim: To evaluate and compare the efficacy of Vidarikanda churna and Kataka churna in the management of male sexual function and poor vision.Materials and Methods: 110 patients who had Timira (refractive errors) with associated symptoms of male sexual dysfunction (MSD) were selected for randomized control trial on the basis of prepared inclusion and exclusion criteria; out of them 50 patients each were divided in two groups (excluding drop outs)named Group A and Group B.Results: The trial drug Kataka churna showed statistically significant results in subjective parameters of visual disturbances (Timira roga) and visual acuity. Vidarikanda churna significantly improved the quality of vision and MSD.Conclusion: The study overall concluded that Shukravradhaka drugs like Vidarikanda significantly improve the quality of vision

Global Medical Device Nomenclature: The Concept for Reducing Device-Related Medical Errors

In the medical device field, there are a number of players, having quite different responsibilities and levels of understanding of the processes, but all with one common interest, that of ensuring the availability of sound medical devices to the general public. To assist in this very important process, there is a need for a common method for describing and identifying these medical devices in an unambiguous manner. The Global Medical Device Nomenclature (GMDN) now provides, for the first time, an international tool for identifying all medical devices, at the generic level, in a meaningful manner that can be understood by all users. Prior to the GMDN, many nomenclature systems existed, all built upon different structures, and used locally or nationally for special purposes, with unusual approaches. These diverse systems, although often workable in their own right, have had no impact on improving the overall situation of providing a common platform, whereby, medical devices could be correctly identified and the related data safely exchanged between the involved parties. Work by standard organizations such as, CEN (European Committee for Standardization) and ISO (International Organization for Standardization), from 1993 to 1996, resulted in a standard that specified a structure for a new nomenclature, for medical devices. In this article we are trying to explain GMDN as the prime method to reduce medical device errors, and to understand the concept of GMDN, to regulate the medical device throughout the globe. Here we also make an attempt to explain various aspects of the GMDN system, such as, the process of development of the GMDN-CEN report, purpose, benefits, and their structural considerations. In addition, there will be an explanation of the coding system, role of the GMDN agency, and their utilization in the unique device identification (UDI) System. Finally, the current area of focus and vision for the future are also mentioned

To Recognize the Use of International Standards for Making Harmonized Regulation of Medical Devices in Asia-Pacific

‘Medical Devices’ include everything from highly sophisticated, computerized, medical equipment, right down to simple wooden tongue depressors. Regulations embody the public expectations for how buildings and facilities are expected to perform and as such represent public policy. Regulators, who develop and enforce regulations, are empowered to act in the public’s interest to set this policy and are ultimately responsible to the public in this regard. Standardization contributes to the basic infrastructure that underpins society including health and environment, while promoting sustainability and good regulatory practice. The international organizations that produce International Standards are the International Electrotechnical Commission (IEC), the International Organization for Standardization (ISO), and the International Telecommunication Union (ITU). With the increasing globalization of markets, International Standards (as opposed to regional or national standards) have become critical to the trading process, ensuring a level playing field for exports, and ensuring that imports meet the internationally recognized levels of performance and safety. The development of standards is done in response to sectors and stakeholders that express a clearly established need for them. An industry sector or other stakeholder group typically communicates its requirement for standards to one of the national members. To be accepted for development, a proposed work item must receive a majority support of the participating members, who verify the global relevance of the proposed item. The regulatory authority (RA) should provide a method for the recognition of international voluntary standards and for public notification of such recognition. The process of recognition may vary from country to country. Recognition may occur by periodic publication of lists of standards that a regulatory authority has found will meet the Essential Principles. In conclusion, International standards, such as, basic standards, group standards, and product standards, are a tool for harmonizing regulatory processes, to assure the safety, quality, and performance of medical devices. Standards represent the opinion of experts from all interested parties, including industry, regulators, users, and others

Improved Electromagnetic Interference Shielding Properties of MWCNT–PMMA Composites Using Layered Structures

Electromagnetic interference (EMI) shielding effectiveness (SE) of multi-walled carbon nanotubes–polymethyl methacrylate (MWCNT–PMMA) composites prepared by two different techniques was measured. EMI SE up to 40 dB in the frequency range 8.2–12.4 GHz (X-band) was achieved by stacking seven layers of 0.3-mm thick MWCNT–PMMA composite films compared with 30 dB achieved by stacking two layers of 1.1-mm thick MWCNT–PMMA bulk composite. The characteristic EMI SE graphs of the composites and the mechanism of shielding have been discussed. SE in this frequency range is found to be dominated by absorption. The mechanical properties (tensile, flexural strength and modulus) of the composites were found to be comparable or better than the pure polymer. The studies therefore show that the composite can be used as structurally strong EMI shielding material

Qualitative characterization of healthcare wastes

The biological hazard inherent in the clinical wastes should be considered during the management and treatment process as well as the disposal into the environment. In this chapter, the risks associated with the clinical wastes as well as the management of these wastes are discussed. The chapter focused on reviewing the types of healthcare wastes generated from hospitals and clinics as well as the regulations and management practices used for these wastes. Moreover, the health risk associated with the infectious agents which have the potential to be transmitted into the environment. It has appeared that the clinical wastes represent real hazards for the human health and the environment if they were not managed properly

On using visibility correlations to probe the HI distribution from the dark ages to the present epoch I: Formalism and the expected signal

Redshifted 21 cm radiation originating from the cosmological distribution of neutral hydrogen (HI) appears as a background radiation in low frequency radio observations. The angular and frequency domain fluctuations in this radiation carry information about cosmological structure formation. We propose that correlations between visibilities measured at different baselines and frequencies in radio-interferometric observations be used to quantify the statistical properties of these fluctuations. This has an inherent advantage over other statistical estimators in that it deals directly with the visibilities which are the primary quantities measured in radio-interferometric observations. Also, the visibility correlation has a very simple relation with power spectrum. We present estimates of the expected signal for nearly the entire post-recombination era, from the dark ages to the present epoch. The epoch of reionization, where the HI has a patchy distribution, has a distinct signature where the signal is determined by the size of the discrete ionized regions. The signal at other epochs, where the HI follows the dark matter, is determined largely by the power spectrum of dark matter fluctuations. The signal is strongest for baselines where the antenna separations are within a few hundred times the wavelength of observation, and an optimal strategy would preferentially sample these baselines. In the frequency domain, for most baselines the visibilities at two different frequencies are uncorrelated beyond \Delta \nu ~ 1 MHz, a signature which in principle would allow the HI signal to be easily distinguished from the continuum sources of contamination.Comment: 12 pages, 9 figures, Accepted to MNRAS; Replaced to match version accepted in MNRA

GMRT observation towards detecting the Post-reionization 21-cm signal

We have analyzed 610 MHz GMRT observations towards detecting the redshifted 21-cm signal from z=1.32. The multi-frequency angular power spectrum C_l(Delta nu) is used to characterize the statistical properties of the background radiation across angular scales ~20" to 10', and a frequency bandwidth of 7.5 MHz with resolution 125 kHz. The measured C_l(Delta nu) which ranges from 7 mK^2 to 18 mK^2 is dominated by foregrounds, the expected HI signal C_l^HI(Delta nu) ~10^{-6}- 10^{-7} mK^2 is several orders of magnitude smaller. The foregrounds, believed to originate from continuum sources, is expected to vary smoothly with Delta nu whereas the HI signal decorrelates within ~0.5 MHz and this holds the promise of separating the two. For each l, we use the interval 0.5 < Delta nu < 7.5 MHz to fit a fourth order polynomial which is subtracted from the measured C_l(Delta nu) to remove any smoothly varying component across the entire bandwidth Delta nu < 7.5 MHz. The residual C_l(Delta nu), we find, has an oscillatory pattern with amplitude and period respectively ~0.1 mK^2 and Delta nu = 3 MHz at the smallest l value of 1476, and the amplitude and period decreasing with increasing l. Applying a suitably chosen high pass filter, we are able to remove the residual oscillatory pattern for l=1476 where the residual C_l(Delta nu) is now consistent with zero at the 3-sigma noise level. We conclude that we have successfully removed the foregrounds at l=1476 and the residuals are consistent with noise. We use this to place an upper limit on the HI signal whose amplitude is determined by x_HI b where x_HI and b are the HI neutral fraction and the HI bias respectively. A value of x_HI b greater than 7.95 would have been detected in our observation, and is therefore ruled out at the 3-sigma level. (abridged)Comment: 29 pages, 13 figures, Accepted to MNRA

Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers

Human endogenous retroviruses (HERV) form a substantial part of the human genome, but mostly remain transcriptionally silent under strict epigenetic regulation, yet can potentially be reactivated by malignant transformation or epigenetic therapies. Here, we evaluate the potential for T cell recognition of HERV elements in myeloid malignancies by mapping transcribed HERV genes and generating a library of 1169 potential antigenic HERV-derived peptides predicted for presentation by 4 HLA class I molecules. Using DNA barcode-labeled MHC-I multimers, we find CD8+ T cell populations recognizing 29 HERV-derived peptides representing 18 different HERV loci, of which HERVH-5, HERVW-1, and HERVE-3 have more profound responses; such HERV-specific T cells are present in 17 of the 34 patients, but less frequently in healthy donors. Transcriptomic analyses reveal enhanced transcription of the HERVs in patients; meanwhile DNA-demethylating therapy causes a small and heterogeneous enhancement in HERV transcription without altering T cell recognition. Our study thus uncovers T cell recognition of HERVs in myeloid malignancies, thereby implicating HERVs as potential targets for immunotherapeutic therapies

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features underpinning CPI sensitization. Here, we collated whole-exome and transcriptomic data for >1,000 CPI-treated patients across seven tumor types, utilizing standardized bioinformatics workflows and clinical outcome criteria to validate multivariable predictors of CPI sensitization. Clonal tumor mutation burden (TMB) was the strongest predictor of CPI response, followed by total TMB and CXCL9 expression. Subclonal TMB, somatic copy alteration burden, and histocompatibility leukocyte antigen (HLA) evolutionary divergence failed to attain pan-cancer significance. Dinucleotide variants were identified as a source of immunogenic epitopes associated with radical amino acid substitutions and enhanced peptide hydrophobicity/immunogenicity. Copy-number analysis revealed two additional determinants of CPI outcome supported by prior functional evidence: 9q34 (TRAF2) loss associated with response and CCND1 amplification associated with resistance. Finally, single-cell RNA sequencing (RNA-seq) of clonal neoantigen-reactive CD8 tumor-infiltrating lymphocytes (TILs), combined with bulk RNA-seq analysis of CPI-responding tumors, identified CCR5 and CXCL13 as T-cell-intrinsic markers of CPI sensitivity

Antiproliferative effect of Tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines

<p>Abstract</p> <p>Background</p> <p>The treatment of oral squamous cell carcinomas (OSCC) and human osteosarcoma (HOS) includes surgery and/or radiotherapy which often lead to reduced quality of life. This study was aimed to study the antiproliferative activity of local honey (Tualang) on OSCC and HOS cell lines.</p> <p>Methods</p> <p>Several concentrations of Tualang honey (1% - 20%) were applied on OSCC and HOS cell lines for 3, 6, 12, 24, 48 and 72 hours. Morphological characteristics were observed under light and fluorescent microscope. Cell viability was assessed using MTT assay and the optical density for absorbance values in each experiment was measured at 570 nm by an ELISA reader. Detection of cellular apoptosis was done using the Annexin V-FITC Apoptosis Detection Kit.</p> <p>Results</p> <p>Morphological appearance showed apoptotic cellular changes like becoming rounded, reduction in cell number, blebbed membrane and apoptotic nuclear changes like nuclear shrinkage, chromatin condensation and fragmented nucleus on OSCC and HOS cell lines. Cell viability assay showed a time and dose-dependent inhibitory effect of honey on both cell lines. The 50% inhibitory concentration (IC_<b>50</b>) for OSCC and HOS cell lines was found to be 4% and 3.5% respectively. The maximum inhibition of cell growth of ≥80% was obtained at 15% for both cell lines. Early apoptosis was evident by flow cytometry where percentage of early apoptotic cells increased in dose and time dependent manner.</p> <p>Conclusion</p> <p>Tualang honey showed antiproliferative effect on OSCC and HOS cell lines by inducing early apoptosis.</p